MRI T2-Weighted Imaging and Fat-Suppressed T2-Weighted Imaging Image Fusion Technology Improves Image Discriminability for the Evaluation of Anal Fistulas

Shi-Ting Feng,Mengqi Huang,Zhi Dong,Ling Xu,Yin Li,Yingmei Jia,Huasong Cai,Bingqi Shen,Zi-Ping Li 대한영상의학회 2019 Korean Journal of Radiology Vol.20 No.3

Objective: To explore whether MRI fusion technology (combined T2-weighted imaging [T2WI] and fat-suppressed T2WI [T2WI-FS]) improves signal differences between anal fistulas and surrounding structures. Materials and Methods: A total of 32 patients with confirmed diagnoses of anal fistula were retrospectively studied. All available T2WI and T2WI-FS images for each patient were used to generate fusion image (T2WI-Fusion) based on the addition of gray values obtained from each pixel via an MR post-processing work station. The discriminability of fistula, perianal sphincter, and perianal fat in T2WI, T2WI-FS, and T2WI-Fusion images was quantified with Fisher’s scoring algorithm. For subjective visual image assessment by researchers, five-point scale scores were determined using a modified double-stimulus continuous qualityscale test to evaluate T2WI-FS, T2WI, enhanced axial three-dimensional-volumetric interpolated breath-hold examination (3D-VIBE), and T2WI-Fusion sequence images. The differences were subsequently compared. Results: Mean Fisher scores for fistulas vs. sphincters obtained from T2WI-Fusion (FFusion-fistula = 6.56) were significantly higher than those from T2WI (FT2WI-fistula = 3.35) (p = 0.001). Mean Fisher scores for sphincters vs. fat from T2WI-Fusion (FFusion-sphincter = 10.84) were significantly higher than those from T2WI-FS (FSFS-sphincter = 2.57) (p = 0.001). In human assessment, T2WI-Fusion showed the same fistula discriminability as T2WI-FS, and better sphincter discriminability than T2WI. Overall, T2WI-Fusion showed better discriminability than T2WI, T2WI-FS, and enhanced 3D-VIBE images. Conclusion: T2WI and T2WI-FS fusion technology improves signal differences between anal fistulas and surrounding structures, and may facilitate better evaluation of anal fistulas and sphincters.

A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study

Ting-Yan Shi,Sheng Yin,Jianqing Zhu,Ping Zhang,Jihong Liu,Libing Xiang,Yaping Zhu,Sufang Wu,Xiaojun Chen,Xipeng Wang,Yin-Cheng Teng,Tao Zhu,Aijun Yu,Yingli Zhang,Yanling Feng,He Huang,Wei Bao,Yanli Li 대한부인종양학회 2020 Journal of Gynecologic Oncology Vol.31 No.3

Background: In China, secondary cytoreductive surgery (SCR) has been widely used in ovarian cancer (OC) over the past two decades. Although Gynecologic Oncology Group-0213 trial did not show its overall survival benefit in first relapsed patients, the questions on patient selection and effect of subsequent targeting therapy are still open. The preliminary data from our pre-SOC1 phase II study showed that selected patients with second relapse who never received SCR at recurrence may still benefit from surgery. Moreover, poly(ADP-ribose) polymerase inhibitors (PARPi) maintenance now has been a standard care for platinum sensitive relapsed OC. To our knowledge, no published or ongoing trial is trying to answer the question if patient can benefit from a potentially complete resection combined with PARPi maintenance in OC patients with secondary recurrence. Methods: SOC-3 is a multi-center, open, randomized, controlled, phase II trial of SCR followed by chemotherapy and niraparib maintenance vs chemotherapy and niraparib maintenance in patients with platinum-sensitive second relapsed OC who never received SCR at recurrence. To guarantee surgical quality, if the sites had no experience of participating in any OC-related surgical trials, the number of recurrent lesions evaluated by central-reviewed positron emission tomography–computed tomography image shouldn't be more than 3. Eligible patients are randomly assigned in a 1:1 ratio to receive either SCR followed by 6 cycles of platinum-based chemotherapy and niraparib maintenance or 6 cycles of platinum-based chemotherapy and niraparib maintenance alone. Patients who undergo at least 4 cycles of chemotherapy and must be, in the opinion of the investigator, without disease progression, will be assigned niraparib maintenance. Major inclusion criteria are secondary relapsed OC with a platinum-free interval of no less than 6 months and a possibly complete resection. Major exclusion criteria are borderline tumors and non-epithelial ovarian malignancies, received debulking surgery at recurrence and impossible to complete resection. The sample size is 96 patients. Primary endpoint is 12-month non-progression rate. Trial Registration: ClinicalTrials.gov Identifier: NCT03983226

Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum- sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study

Ting-Yan Shi,Libing Xiang,Jianqing Zhu,Ji-hong Liu,Ping Zhang,Hua-ying Wang,Yanling Feng,Tao Zhu,Yingli Zhang,Aijun Yu,Wei Jiang,Xipeng Wang,Yaping Zhu,Sufang Wu,Yincheng Teng,Jiejie Zhang,Rong Jiang 대한부인종양학회 2022 Journal of Gynecologic Oncology Vol.33 No.4

Phase II trial of VEGFR2 inhibitor apatinib for metastatic sarcoma: focus on efficacy and safety

Zhichao Liao,Feng Li,Chao Zhang,Lei Zhu,Yehui Shi,Gang Zhao,Xu Bai,Shafat Hassan,Xinyue Liu,Ting Li,Peipei Xing,Jun Zhao,Jin Zhang,Ruwei Xing,Sheng Teng,Yun Yang,Kexin Chen,Jilong Yang 생화학분자생물학회 2019 Experimental and molecular medicine Vol.51 No.-

Apatinib (YN968D1) is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR- 2). We conducted a single-arm, nonrandomized phase II study (NCT03121846) to assess the efficacy and safety of apatinib in patients with stage IV sarcoma. We recruited 64 patients with stage IV sarcoma who had failed chemotherapy. The primary endpoint was progression-free survival (PFS), and the secondary endpoints were progression-free survival rate (PFR), objective response rate (ORR), and disease control rate (DCR) at week 12. Treatment-related adverse effects (AEs) were evaluated. Fifty-nine patients were assessed for efficacy and 64 patients for AEs. The median PFS was 7.93 months. At 12 weeks, the PFR was 74%, the ORR was 16.95% (10/59), and the DCR was 86.44% (51/59). The final ORR was 15.25% (9/59) and the DCR was 57.63% (34/59). Notably, 22 patients (34.38%) who developed hypertension, hand-foot-skin reaction, or proteinuria had significantly longer OS than those without these AEs (18.20 vs. 10.73 months; P = 0.002). We conclude that apatinib is effective and well tolerated in patients with advanced sarcoma. The development of hypertension, hand-foot-skin reaction, or proteinuria may indicate a favorable prognosis, representing a novel finding in sarcoma patients.

Recent progresses and perspectives of VN-based materials in the application of electrochemical energy storage

Ling-Na Shi,Xue-Zhong Li,Lan-Tong Cui,Peng-Fei Wang,Ying Xie,Ting-Feng Yi 한국공업화학회 2022 Journal of Industrial and Engineering Chemistry Vol.114 No.-

Developing well-behaved electrode materials is crucial for manufacturing high-performance batteries,SCs and electrocatalysis, and it is also one of the main driving forces for the development of EES devices. In consideration of the high robustness and electrical conductivity during the electrochemical reactionprocess, VN-based materials exhibit good performance as electrode materials (or catalytic materials)for batteries, supercapacitors, and excellent catalytic activity for electrocatalysts. Especially, the VNbasedmaterials decorated into other active compounds with various morphologies elaborately presentexcellent performances due to the abundant active sites and fully synergistic effect. This review presentsthe structure-performance relation by designing different-dimensional nanostructures and various applicationsof VN-based materials in electrochemical energy storage (EES) applications. Finally, the perspectiveson future challenges and progress have been discussed. This review can offer a specificunderstanding for the optimization strategies of VN-based materials, thus booming the rapid developmentand practical applications for EES devices in the future.

Improved lithium storage performance of CeO2-decorated SrLi2Ti6O14 material as an anode for Li-ion battery

Ying Li,Hong-Yan Liu,Ling-Na Shi,Yan-Rong Zhu,Ting-Feng Yi 한국공업화학회 2021 Journal of Industrial and Engineering Chemistry Vol.101 No.-

In this work, the CeO2-decorated SrLi2Ti6O14 anode was successfully prepared through a solid-state process. The space-charge effect induced by the internal adsorption of ions on the CeO2 surface can easilyresult in a formation of an excellent conductive interfacial layer between CeO2 and SrLi2Ti6O14. The goodelectrical contact between CeO2 and SrLi2Ti6O14 offers more active sites for the electrolyte storage andredox reaction, and promotes the intercalation/deintercalation of lithium ions, and thus improves therate performance and cycle stability. Due to its unique structure and composition, the CeO2-decoratedSrLi2Ti6O14 composites exhibit high reversible capacities, good cycle performance and outstanding rateperformance. Especially, the CeO2 (5 wt%)-decorated SrLi2Ti6O14 anode shows the most excellent electrochemicalperformance, which delivers a large charge capacity of 121.3 mAh g 1 and a capacity retentionof 94.48% after 100 cycles at 0.5 A g 1. However, the corresponding charge capacity and capacity retentionof pristine SrLi2Ti6O14 are 100.5 mAh g 1 and 86.77%, respectively. The CeO2(5 wt%)-decoratedSrLi2Ti6O14 with enhanced rate capacity, cycle stability and structural stability is a potential electrodematerial candidate for Li-ion battery.